Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...

In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

Neurizon Therapeutics continues to make strides on its NUZ-001 treatment for ALS, paving the way for next stage clinical trials. In this episode, Tylah Tully gives the skinny on Neurizon ...

Neurizon Therapeutics (ASX:NUZ) has shared an update on its preparations for its HEALEY ALS Platform Trial – a multicentre, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

"All the indications have high unmet need and large markets," Jain said. Neurizon Therapeutics (ASX:NUZ) is targeting amyotrophic lateral sclerosis (ALS), the most common form of motor neurone ...